B
CORT icon

Bailard’s Corcept Therapeutics CORT Stock Holding History

Bailard’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$237K Buy
+2,060
New +$222K ﹤0.01% 684
2025
Q4 		– Sell
-2,713
Closed -$225K – 772
2025
Q3 		$225K Buy
+2,713
New +$196K ﹤0.01% 704
2025
Q2 		– Sell
-2,712
Closed -$310K – 772
2025
Q1 		$310K Buy
+2,712
New +$165K 0.01% 564
2024
Q4 		– Sell
-4,612
Closed -$213K – 747
2024
Q3 		$213K Buy
+4,612
New +$164K 0.01% 698

Other funds holding CORT

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
VFP
Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.66B AUM 22.28% 1-Year Est. Return
UWS
Unique Wealth Strategies Burr Ridge, Illinois $273M AUM 19.98% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return

Bailard's CORT Position: Q3 2026 in Review

Bailard opened a new position in Corcept Therapeutics (CORT) in Q3 2026: 2,060 shares worth $237K. The stake represents ﹤0.01% of the portfolio and ranks #684 among its holdings. This is a return to the name: Bailard previously reported a position in CORT as recently as Q3 2025.

Bailard first reported a position in CORT in Q3 2024 and has held it in 4 quarters since. The position peaked at $310K in Q1 2025. 20 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Bailard held 2,060 shares of Corcept Therapeutics worth $237K as of Q3 2026.
  • Corcept Therapeutics was a new Bailard position in Q3 2026.
  • Corcept Therapeutics made up ﹤0.01% of Bailard's portfolio in Q3 2026, its #684 holding.
  • Bailard first reported a position in Corcept Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Bailard's Corcept Therapeutics position peaked at $310K in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Bailard's 13F filing for Q3 2026, filed 13 Oct 2026.